Relmada Therapeutics, Inc. acquired global rights to develop and market Dextromethadone.
January 16, 2018
Share
Relmada Therapeutics, Inc. (OTCPK:RLMD) acquired global rights to develop and market Dextromethadone on January 17, 2018.
Relmada Therapeutics, Inc. (OTCPK:RLMD) completed the acquisition of global rights to develop and market Dextromethadone on January 17, 2018.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Companyâs lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
RELMADA THERAPEUTICS, INC. 
